Kazama JJ - Search Results

1

Fukagawa M, Kazama JJ. Fukagawa M, et al. Among authors: kazama jj. Pediatr Nephrol. 2006 Dec;21(12):1802-6. doi: 10.1007/s00467-006-0230-3. Epub 2006 Aug 24. Pediatr Nephrol. 2006. PMID: 16932898 Review.

2

[PTH and bone metabolism in chronic dialysis patients].

Fukagawa M, Kazama J, Shigematsu T. Fukagawa M, et al. Rinsho Byori. 2001 Mar;49(3):236-8. Rinsho Byori. 2001. PMID: 11307321 Review. Japanese.

3

Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases.

Fukagawa M, Kazama JJ, Shigematsu T. Fukagawa M, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S152-5. doi: 10.1053/ajkd.2001.27426. Am J Kidney Dis. 2001. PMID: 11576943 Review.

4

Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients.

Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, Fukagawa M. Nakanishi S, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S172-4. doi: 10.1053/ajkd.2001.27436. Am J Kidney Dis. 2001. PMID: 11576948 Clinical Trial.

5

Osteoprotegerin levels before and after renal transplantation.

Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, Watanabe I, Katayama A, Haba T, Uchida K, Fukagawa M. Sato T, et al. Among authors: kazama jj. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S175-7. doi: 10.1053/ajkd.2001.27437. Am J Kidney Dis. 2001. PMID: 11576949 Clinical Trial.

6

Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.

Kazama JJ, Omori T, Ei I, Ei K, Oda M, Maruyama H, Narita I, Gejyo F, Shigematsu T, Fukagawa M. Kazama JJ, et al. Clin Exp Nephrol. 2003 Jun;7(2):144-9. doi: 10.1007/s10157-003-0226-2. Clin Exp Nephrol. 2003. PMID: 14586733

7

Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism.

Kazama JJ, Suzuki K, Yokoseki A, Oyanagi A, Goto S, Shimada H, Maruyama H, Narita I, Gejyo F. Kazama JJ, et al. Clin Nephrol. 2003 Nov;60(5):369-71. doi: 10.5414/cnp60369. Clin Nephrol. 2003. PMID: 14640244

8

[Adynamic bone disease].

Kazama JJ, Fukagawa M. Kazama JJ, et al. Nihon Rinsho. 2004 Jun;62 Suppl 6:330-3. Nihon Rinsho. 2004. PMID: 15250318 Review. Japanese. No abstract available.

9

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M. Shigematsu T, et al. Among authors: kazama jj. Am J Kidney Dis. 2004 Aug;44(2):250-6. doi: 10.1053/j.ajkd.2004.04.029. Am J Kidney Dis. 2004. PMID: 15264182

10

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M. Sato T, et al. Among authors: kazama jj. Am J Kidney Dis. 2004 Sep;44(3):481-7. Am J Kidney Dis. 2004. PMID: 15332221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters